
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Daniel C. Malone, RPh, PhD, FAMCP, details the process for developing a standardized set of drug interactions.
Daniel C. Malone, RPh, PhD, FAMCP, a professor of pharmacy at the University of Arizona College of Pharmacy, details the process for developing a standardized set of drug interactions.
This interview was recorded at the ASHP 2014 Midyear Clinical Meeting in Anaheim, California.






